Race does not predict skeletal‐related events and all‐cause mortality in men with castration‐resistant prostate cancer
Abstract
Background: The impact of race on prostate cancer skeletal‐related events (SREs) remains understudied. In the current study, the authors tested the impact of race on time to SREs and overall survival in men with newly diagnosed, bone metastatic castration‐resistant prostate cancer (mCRPC).Methods: The authors performed a retrospective study of patients from 8 Veterans Affairs hospitals who were newly diagnosed with bone mCRPC in the year 2000 or later. SREs comprised pathologic fracture, spinal cord compression, radiotherapy to the bone, or surgery to the bone. Time from diagnosis of bone mCRPC to SREs and overall mortality was estimated using the Kaplan‐Meier method. Cox models tested the association between race and SREs and overall mortality.Results: Of 837 patients with bone mCRPC, 232 patients (28%) were black and 605 (72%) were nonblack. At the time of diagnosis of bone mCRPC, black men were found to be more likely to have more bone metastases compared with nonblack men (29% vs 19% with ≥10 bone metastases; P = .021) and to have higher prostate‐specific antigen (41.7 ng/mL vs 29.2 ng/mL; P = .005) and a longer time from the diagnosis of CRPC to metastasis (17.9 months vs 14.3 months; P < .01). On multivariable analysis, there were no differences noted with regard to SRE risk (hazard ratio [HR], 0.80; 95% CI, 0.59‐1.07) or overall mortality (HR, 0.87; 95% CI, 0.73‐1.04) between black and nonblack people, although the HRs were <1, which suggested the possibility of better outcomes.Conclusions: No significant association between black race and risk of SREs and overall mortality was observed in the current study. These data have suggested that efforts to understand the basis for the excess risk of aggressive prostate cancer in black men should focus on cancer development and progression in individuals with early‐stage disease.Keywords
This publication has 24 references indexed in Scilit:
- Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year periodCancer, 2014
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical PracticeJournal of Clinical Oncology, 2011
- Defining Ethnic and Racial Differences in Osteoporosis and Fragility FracturesClinical Orthopaedics and Related Research, 2011
- What is the real impact of bone pain on survival in patients with metastatic hormone‐refractory prostate cancer treated with docetaxel?BJU International, 2009
- Racial Differences in Rate of Decline in Bone Mass in Older Men: The Baltimore Men's Osteoporosis StudyJournal of Bone and Mineral Research, 2005
- Osteoporosis and Fracture Risk in Women of Different Ethnic GroupsJournal of Bone and Mineral Research, 2005
- Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancerUrology, 2004
- Impact of race on survival in men with metastatic hormone-refractory prostate cancerUrology, 2004
- Racial and Ethnic Disparities in the Receipt of Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2002
- Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health ProfessionalsJNCI: Journal of the National Cancer Institute, 2000